JEIL PHARMA HOLDINGS Discloses Corporate Governance Report: Some Key Indicators Not Met, Continuous Improvement Plans Announced
JEIL PHARMA HOLDINGS (the 'Company') is a holding company controlling subsidiaries including JEIL PHARM, with the largest shareholder Han Seung-soo and six others holding 73.16%, and minority shareholders 16.11%.
On a consolidated basis, revenue reached 657.6B KRW, operating profit 38.7B KRW, and net profit 34.6B KRW, turning from a net loss of 66.4B KRW in the prior period.
The Company complied with 10 out of 15 key corporate governance indicators (66.7%), with non-compliance areas including failure to announce shareholder meetings 4 weeks in advance, lack of dividend predictability, no annual dividend policy communication, independent director as board chair, and cumulative voting.
The 66th ordinary general meeting was held on March 24, 2026, avoiding peak dates, with electronic voting introduced and all agenda items approved with over 99.9% approval.
A cash dividend of 70 KRW per share (dividend yield 0.86%) was paid, increased from 50 KRW last year, but dividend policy is not formalized and the dividend decision was made after the record date, reducing predictability.
The board consists of 4 inside directors and 3 outside directors (all on the audit committee), including one accounting/finance expert outside director. The CEO doubles as board chair.
For internal control, the Company obtained integrated ISO 37001 (anti-bribery) and ISO 37301 (compliance management) certification, operates a compliance management division, and has enhanced its internal accounting control system.
A CEO succession policy was newly established in 2025, and risk management policies and an internal audit team (1 manager) are in place.
The audit committee holds quarterly meetings with external auditors without management, and oversees external auditor appointment and audit results.
[AI Summary]This report transparently discloses the Company's governance status. Despite some non-compliance with key indicators, positive changes such as net profit turnaround, dividend increase, electronic voting adoption, and internal control strengthening are observed. However, areas for improvement remain in dividend predictability and meeting notice period, resulting in a neutral overall assessment.